Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic review

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 6, 2011, Pages 943-951

  Bai, Ming ^a   Qi, Xingshun ^a   Yang, Zhiping ^a   Yin, Zhanxin ^a   Nie, Yongzhan ^a   Yuan, Shanshan ^a   Wu, Kaichun ^a   Han, Guohong ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Child Pugh class score; Hepatic encephalopathy; Predictor; Transjugular intrahepatic portosystemic shunt

Indexed keywords

CHILD PUGH SCORE; DISEASE CLASSIFICATION; DISEASE SEVERITY; GROUPS BY AGE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MEDICAL HISTORY; POSTOPERATIVE COMPLICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

EID: 79955882605     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06663.x     Document Type: Review

References (49)

1. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010; 51: 306.
2. Gines P, Angeli P, Lenz K etal. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 2010; 53: 397-417.
3. Amarapurkar D, Sanyal A. Improving survival in patients with decompensated cirrhosis. J. Gastroenterol. Hepatol. 2010; 25: 1716-17.
4. Garcia-Pagan JC, Caca K, Bureau C etal. Early use of TIPS in patients with cirrhosis and variceal bleeding. N. Engl. J. Med. 2010; 362: 2370-9.
5. Han G, Qi X, He C etal. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J. Hepatol. 2011; 54: 78-88.
6. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400.
7. Yang Z, Han G, Wu Q etal. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J. Gastroenterol. Hepatol. 2010; 25: 1718-25.
8. Barrio J, Ripoll C, Banares R etal. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. Eur. J. Radiol. 2005; 55: 120-4.
9. Bureau C, Pagan JC, Layrargues GP etal. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007; 27: 742-7.
10. Riggio O, Angeloni S, Salvatori FM etal. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am. J. Gastroenterol. 2008; 103: 2738-46.
11. Mamiya Y, Kanazawa H, Kimura Y etal. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol. Res. 2004; 30: 162-8.
12. Bass NM, Mullen KD, Sanyal A etal. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 2010; 362: 1071-81.
13. Riggio O, Masini A, Efrati C etal. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J. Hepatol. 2005; 42: 674-9.
14. Somberg KA, Riegler JL, LaBerge JM etal. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am. J. Gastroenterol. 1995; 90: 549-55.
15. Riggio O, Merlli M, Pedretti G etal. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig. Dis. Sci. 1996; 41: 578-84.
16. Rossle M, Deibert P, Haag K etal. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349: 1043-9.
17. Escorsell A, Banares R, Garcia-Pagan JC etal. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002; 35: 385-92.
18. Pomier-Layrargues G, Villeneuve JP, Deschenes M etal. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 2001; 48: 390-6.
19. Rossle M, Haag K, Ochs A etal. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N. Engl. J. Med. 1994; 330: 165-71.
20. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP 3rd, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20: 46-55.
21. Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J. Hepatol. 1995; 23: 123-8.
22. Cabrera J, Maynar M, Granados R etal. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110: 832-9.
23. Jabbour N, Zajko AB, Orons PD etal. Transjugular intrahepatic portosystemic shunt in patients with end-stage liver disease: results in 85 patients. Liver Transpl. Surg. 1996; 2: 139-47.
24. Martinet JP, Fenyves D, Legault L etal. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig. Dis. Sci. 1997; 42: 161-6.
25. Sauer P, Theilmann L, Stremmel W, Benz C, Richter GM, Stiehl A. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997; 113: 1623-31.
26. Zuckerman DA, Darcy MD, Bocchini TP, Hildebolt CF. Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. AJR Am. J. Roentgenol. 1997; 169: 1727-31.
27. Casado M, Bosch J, Garcia-Pagan JC etal. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-303.
28. Nolte W, Wiltfang J, Schindler C etal. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 1998; 28: 1215-25.
29. Garcia-Villarreal L, Martinez-Lagares F, Sierra A etal. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999; 29: 27-32.
30. Hassoun Z, Deschenes M, Lafortune M etal. Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy. Am. J. Gastroenterol. 2001; 96: 1205-9.
31. Patel NH, Sasadeusz KJ, Seshadri R etal. Increase in hepatic arterial blood flow after transjugular intrahepatic portosystemic shunt creation and its potential predictive value of postprocedural encephalopathy and mortality. J. Vasc. Interv. Radiol. 2001; 12: 1279-84.
32. Gines P, Uriz J, Calahorra B etal. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-47.
33. Jalan R, Bzeizi KI, Tripathi D, Lui HF, Redhead DN, Hayes PC. Impact of transjugular intrahepatic portosystemic stent-shunt for secondary prophylaxis of oesophageal variceal haemorrhage: a single-centre study over an 11-year period. Eur. J. Gastroenterol. Hepatol. 2002; 14: 615-26.
34. Sauer P, Hansmann J, Richter GM, Stremmel W, Stiehl A. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy 2002; 34: 690-7.
35. Rossi P, Salvatori FM, Fanelli F etal. Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 2004; 231: 820-30.
36. ter Borg PC, Hollemans M, Van Buuren HR etal. Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9years. Radiology 2004; 231: 537-45.
37. Tripathi D, Helmy A, Macbeth K etal. Ten years' follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Eur. J. Gastroenterol. Hepatol. 2004; 16: 9-18.
38. Deng D, Liao MS, Qin JP, Li XA. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy. Hepatobiliary Pancreat. Dis. Int. 2006; 5: 232-6.
39. Tripathi D, Ferguson J, Barkell H etal. Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents. Eur. J. Gastroenterol. Hepatol. 2006; 18: 225-32.
40. Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM 2008; 101: 493-501.
41. Chen L, Xiao T, Chen W etal. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial. Liver Int. 2009; 29: 1101-9.
42. Thalheimer U, Leandro G, Samonakis DN etal. TIPS for refractory ascites: a single-centre experience. J. Gastroenterol. 2009; 44: 1089-95.
43. Parsons-Smith BG, Summerskill WH, Dawson AM, Sherlock S. The electroencephalograph in liver disease. Lancet 1957; 273: 867-71.
44. Conn HO, Leevy CM, Vlahcevic ZR etal. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573-83.
45. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
46. Ochs A. Transjugular intrahepatic portosystemic shunt. Dig. Dis. 2005; 23: 56-64.
47. Garcia-Tsao G. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3: 380-9.
48. Moher D, Pham B, Klassen TP etal. What contributions do languages other than English make on the results of meta-analyses? J. Clin. Epidemiol. 2000; 53: 964-72.
49. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320: 1574-7.